	US 12,324,793 B2
	Method for renal protection
Michiaki Abe, Sendai (JP); Seizo Koshiba, Sendai (JP); Koichiro Nishioka, Tokyo (JP); Kazuhiko Kawaguchi, Tokyo (JP); Satomi Yamasaki, Tokyo (JP); and Yasuyuki Teranaka, Tokyo (JP)
Assigned to TOHOKU UNIVERSITY, Sendai (JP); and NIPPON CHEMIPHAR CO., LTD., Tokyo (JP)
Appl. No. 17/284,862
Filed by TOHOKU UNIVERSITY, Sendai (JP); and NIPPON CHEMIPHAR CO., LTD., Tokyo (JP)
PCT Filed Oct. 17, 2019, PCT No. PCT/JP2019/040995 § 371(c)(1), (2) Date Apr. 13, 2021, PCT Pub. No. WO2020/080499, PCT Pub. Date Apr. 23, 2020.
Claims priority of application No. 2018-195568 (JP), filed on Oct. 17, 2018; application No. 2018-195810 (JP), filed on Oct. 17, 2018; application No. 2019-032126 (JP), filed on Feb. 25, 2019; application No. 2019-086945 (JP), filed on Apr. 28, 2019; and application No. 2019-119297 (JP), filed on Jun. 27, 2019.
Prior Publication US 2021/0386696 A1, Dec. 16, 2021
Int. Cl. A61K 31/194 (2006.01); A61P 13/02 (2006.01); A61P 13/12 (2006.01)

CPC A61K 31/194 (2013.01) [A61P 13/02 (2018.01); A61P 13/12 (2018.01)]

8 Claims

1. A method for renal protection in a mammalian subject suffering from chronic kidney disease, comprising administering to a subject in need of the renal protection an effective amount of a pharmaceutical composition comprising a mixture of sodium citrate or a hydrate thereof and potassium citrate or a hydrate thereof, wherein the renal protection is one or more selected from the group consisting of:

(i) suppression of increase in 8-OHdG concentration in urine,

(ii) suppression of increase in β₂-microglobulin concentration in urine,

(iii) suppression of the increase in albumin concentration in urine,

(iv) suppression of increase in protein concentration in urine, and

(v) suppression of the decrease in osmotic pressure of urine; and

wherein the mammalian subject is not suffering from metabolic acidosis.